U.S. Logistics Stock News

Event context for CONMED and recent performance snapshot Recent commentary on CONMED (CNMD) highlights adoption of its AirSeal, Buffalo Filter, and BioBrace platforms alongside tariff and product specific growth risks. Investors are weighing this product mix against the stock’s recent share price moves. See our latest analysis for CONMED. At a share price of US$49.26, CONMED has seen its 30 day share price return of 14.03% and 90 day share price return of 33.10% contrast with a 1 year total...

Baidu (BIDU) is back in focus after its latest earnings release on August 18, 2026, which showed lower sales and net income compared with a year earlier, prompting investors to reassess the stock. See our latest analysis for Baidu. The latest earnings setback has been mirrored in Baidu's trading, with the share price at US$90.87 and recent share price returns down 12.73% over one day, 15.26% over 30 days, and 39.54% year to date, while the 1 year total shareholder return is positive at 2.02%...

Why BBB Foods Stock Is Back In Focus After Earnings And Capital Plans BBB Foods (TBBB) is drawing attention after reporting second quarter and half year results that paired higher revenue with wider net losses, followed closely by a large shelf registration for potential share issuance. See our latest analysis for BBB Foods. The recent earnings update and US$1.53b shelf registration appear to have sharpened focus on BBB Foods, with the share price at US$48.06 after a 7 day share price return...

Long term Treasury yields near multi decade highs are reshaping where credit risk feels most exposed. AI and tech stocks tied to heavy spending are being repriced as debt, not just growth stories, which is pulling attention toward listed private credit and alternative lenders. This article walks through three stocks from that universe that appear well positioned relative to these shocks and explains how their exposure to the news could matter for your portfolio. The three listed private...

Brinker International recently reported past fourth-quarter and full-year 2026 results, with revenue rising to US$1,535.8 million for the quarter and US$5,807.4 million for the year, alongside higher net income and earnings per share from continuing operations than the prior year. The company also lifted its remaining share repurchase authorization to US$750 million and issued fiscal 2027 revenue guidance of US$6.15–US$6.27 billion, while multiple executives executed largely tax-related or...

DXP Enterprises reported past second-quarter 2026 results showing sales of US$576.46 million and net income of US$28.71 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Over the first half of 2026, DXP’s higher sales and earnings, alongside prior commentary about strong long-term revenue and earnings-per-share expansion, highlight how its growth initiatives are translating into improved profitability. With this earnings strength...

Trane Technologies (TT) drew investor attention after announcing a collaboration with Eaton focused on integrated thermal management and electrical architectures for AI data centers. The move highlights the stock’s exposure to AI infrastructure and energy efficiency themes. See our latest analysis for Trane Technologies. Trane Technologies’ share price has pulled back in the short term, with a 7 day share price return of 4.25% and a 30 day share price return of 1.41%. Longer term total...

Rising sovereign bond yields in Europe are putting fresh attention on companies with solid finances and clear access to long term funding. When borrowing costs climb, weaker balance sheets can feel the strain first, which can create opportunities for investors who focus on financial strength. This article looks at three stocks from the Financially Strong Drone Defense Stocks screener and explains why their balance sheet quality may matter in the current environment. The three drone defense...

In August 2026, Oruka Therapeutics, Inc. reported second-quarter and six-month results showing net losses of US$41.21 million and US$73.03 million, respectively, with basic loss per share from continuing operations rising to US$0.55 for the quarter and US$1.04 for the half year compared with the prior period. The results highlight that Oruka’s losses and loss per share have increased compared with a year earlier, sharpening investor focus on how the company is funding and pacing its...

AtaiBeckley (ATAI) drew fresh attention after releasing second quarter 2026 results, reporting revenue of US$1.7 million and a net loss of US$32.52 million, while loss per share from continuing operations improved year over year. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent earnings release comes after a sharp shift in sentiment, with a 90 day share price return of 78.24% and a 3 year total shareholder return above 300%, although the 5 year total shareholder return remains...

Semtech recently completed the sale of its cellular module business for US$62,000,000, sharpening its focus on AI data-center networking and LoRa-based connectivity solutions. This portfolio shift marks a clearer emphasis on higher-growth connectivity platforms, potentially reshaping how the company allocates capital and prioritizes innovation across its core segments. We’ll now examine how this exit from the cellular module business may influence Semtech’s broader investment narrative...

In early August 2026, Republic Services, Inc. raised its full-year 2026 guidance to US$17.20–US$17.30 billion in revenue, US$2.21–US$2.22 billion in net income, and US$7.18–US$7.23 in diluted EPS, alongside reporting higher second-quarter sales of US$4.43 billion and net income of US$566 million compared with the prior year. The company also completed a US$1.99 billion share repurchase program, shrinking its share count while updating guidance that points to management’s confidence in...

In August 2026, Enovis Corporation reported second-quarter 2026 results showing sales of US$582.78 million and a reduced net loss of US$1.19 million, while six-month sales reached US$1.17 billion with a smaller net loss of US$9.95 million compared with the prior year. At the same time, Enovis reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic revenue growth, underscoring management’s confidence in the business trajectory despite losses. We will...

Recent Share Performance Context Luckin Coffee (OTCPK:LKNC.Y) has drawn fresh attention after its recent price move, with the stock closing at $36.45 as of 17 August 2026 and showing mixed return patterns across different time frames. Over the past day, week and month, Luckin Coffee has recorded returns of 1.53%, 6.83% and 19.12% respectively. Over the past 3 months, the stock shows an 11.81% gain, while the past year reflects a 3.32% decline. See our latest analysis for Luckin Coffee. The...

Entergy stock has delivered very strong returns over the past three years, yet the current valuation signals are cautious, with the Dividend Discount Model (DDM) implying the shares trade at a premium to its estimated intrinsic value while the broader checks do not point to a clear bargain. Entergy has returned 151.5% over the past three years, which puts recent gains under the spotlight when judging whether the current price still offers an attractive entry point. Expectations for steady...

Erasca (ERAS) is back in focus after reporting second quarter 2026 results that showed a wider net loss, alongside the appointment of veteran oncology leader Charles S. Fuchs as president of research and development. See our latest analysis for Erasca. Erasca’s recent earnings release, shelf registration filing of up to US$112.344 million and the ongoing securities class action have all landed while the stock trades at US$18.10, with a 90 day share price return of 55.97% and a year to date...

Rhythm Pharmaceuticals (RYTM) stock is in focus after the company appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer on 17 August 2026, adding experienced leadership in rare disease drug development. See our latest analysis for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals has seen momentum build over 2026, with a 30 day share price return of 8.11% and a 90 day share price return of 27.15%, while the 1 year total shareholder return of 18.58% sits against a very large 5 year total...

Acuity Inc. has appointed Ruth Gratzke as President of Acuity Brands Lighting, effective 1 September 2026, bringing more than 25 years of leadership experience across industrial technology, smart infrastructure and electrical products, and she will report directly to CEO Neil Ashe. Her track record at Siemens in scaling complex smart infrastructure portfolios and advancing digital and energy-efficient solutions gives Acuity additional executive depth in areas closely linked to its lighting...

Recent commentary on Gartner (IT) has focused on stronger earnings estimates, consistent revenue growth, and solid free cash flow, along with an active share repurchase program that together appear to be shaping current investor attention. See our latest analysis for Gartner. Gartner's recent 1 month share price return of 29.87% and 90 day share price return of 14.90% contrast with a year to date share price decline of 23.19% and a 1 year total shareholder return decline of 25.04%. Together,...

Schrödinger (SDGR) is back in focus after reporting second quarter 2026 results that moved from a loss to a profit, along with a new agreement to deploy its Bunsen AI co-scientist with Bristol Myers Squibb. See our latest analysis for Schrödinger. At a share price of $17.67, Schrödinger has seen a 43.4% 90 day share price return and a 15.3% 30 day share price return, although the 1 year total shareholder return is down 8.9%. This suggests recent momentum has picked up following the move to...

Oncolytics Biotech has received FDA feedback supporting a potential pivotal expansion of its REO 033 colorectal cancer trial.

Optimi Health has added financial flexibility to its growth strategy as it advances its MDMA and psilocybin business.

ADMA Biologics (ADMA) stock is back in focus after the company reported second quarter 2026 results, highlighted by US$124.4 million in sales and US$37.82 million in net income, along with reaffirmed full year revenue guidance. See our latest analysis for ADMA Biologics. At a share price of US$9.54, ADMA Biologics has seen a 1 month share price return of 9.53% and a 3 month share price return of 11.45%. However, the year to date share price return is down 46.64%, while the 5 year total...

Recent coverage of BGC Group highlights its expanding global brokerage and financial technology platform, including the Fenics and FMX businesses and a new prediction markets partnership, alongside reported strength in revenue and earnings per share growth over the past two years. This combination of diversification across trading platforms and commentary about a potentially attractive valuation has drawn fresh attention to BGC’s investment case among institutional and retail...